
Keywords: Active Ulcerative Colitis; IBD Therapy; Immunosuppressive Agent; Inflammatory Bowel Diseases; AE; adverse event; CD; Crohn's disease; FCP; fecal calprotectin; IBD; inflammatory bowel disease; MERIT-UC; Methotrexate Response in Treatment of Ulcerative Co